# Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)

> **NCT05170269** · PHASE3 · TERMINATED · sponsor: **Biotest** · enrollment: 48 (actual)

## Conditions studied

- Congenital Cytomegalovirus Infection

## Interventions

- **DRUG:** BT097

## Key facts

- **NCT ID:** NCT05170269
- **Lead sponsor:** Biotest
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-17
- **Primary completion:** 2023-11-19
- **Final completion:** 2024-03-29
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170269, "Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05170269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*